3D Medicines Inc. (01244) disclosed inside information on August 1 regarding the final ruling from the Hong Kong International Arbitration Centre on a cross-border licensing dispute arbitration with SELLAS Life Sciences Group, Inc. The sole arbitrator fully dismissed all of SELLAS's arbitration claims and ordered SELLAS to bear approximately HK$8 million in related costs incurred by 3D Medicines in this arbitration. These costs must be fully paid by August 7, with interest accruing at an annual rate of 8% for any overdue amount.
Industry analysts believe the key to this ruling lies in the determination that 3D Medicines' commercial arrangements were reasonable, which provides strong protection for the commercial prospects of 3D189 in Greater China. The global, multi-center Phase 3 REGAL study for AML patients in second complete remission (CR2) is progressing, with the primary endpoint being overall survival (OS). According to the latest disclosure, the study has now reached a total of 78 death events, just two short of the 80 required to trigger the final analysis. All efficacy and survival data remain fully blinded, and the Data Safety Monitoring Board has recommended continuing the trial. Historical precedent shows that SELLAS experienced a nearly tenfold increase in market value after receiving approval from the Safety Data Committee to continue clinical trials last year. Against the backdrop of global clinical trials nearing completion and rising market expectations, this legal backing provides the most critical certainty for subsequent regulatory filings and commercial deployment.
The clinical progress of 3D189 has become a focus for the market. For 3D Medicines, a biopharmaceutical company whose valuation is considered severely undervalued, this represents an excellent investment window. It is understood that 3D189 is a first-in-class, WT1-targeting therapeutic tumor vaccine. WT1 is recognized by the U.S. National Cancer Institute as the top-ranked cancer antigen and is broadly expressed in over 20 cancer types. In terms of disease burden, there are approximately 14,000 new AML patients in China annually, with the global treatment market projected to reach $3.9 billion in 2025 and the Asia-Pacific market around $820 million. Furthermore, there has long been a lack of a unified, effective standard regimen for CR2 maintenance therapy. This means that if 3D189 succeeds, it has the potential to become the world's first approved WT1 tumor vaccine, filling a gap in this specific segment.
Broadening the perspective, the WT1 target also covers hematologic malignancies and most solid tumors. The potential for combining 3D189 with immune checkpoint inhibitors, chemotherapy, and other therapies is also promising. Converting clinical value into commercial returns hinges on accurately quantifying the target market. Based on modeling of the AML patient flow in Greater China, the commercial pathway for 3D189 already presents a verifiable financial profile: peak sales of 3D189 for the AML indication in Greater China are estimated to reach 300-400 million RMB, with stable contributions expected over several years. It is important to note that this estimate only covers the single AML indication. The potential expansion into other indications, such as malignant pleural mesothelioma and ovarian cancer, where preliminary clinical data exists, could unlock additional upside. With a clear business model in place, robust execution capability is required for successful implementation. 3D Medicines has a proven track record here—its first commercial product, Envida (the world's first subcutaneously injected PD-L1 single-domain antibody), has benefited tens of thousands of patients over four years since launch, demonstrating the company's complete closed-loop capability from clinical development to commercialization in the tumor immunotherapy field.
The company is currently leveraging its three proprietary R&D platforms (an in vivo CAR-T/NK technology vaccine platform, the AI+mRNA tumor vaccine 3D-preciseAG platform, and a radiopharmaceutical conjugate RDC platform) to build a dedicated academic promotion system for tumor vaccines, making early preparations for the market introduction of 3D189 post-launch. The complete resolution of arbitration uncertainty further solidifies the cooperative relationship between the two parties within a legal framework. Coupled with the key catalyst of the imminent REGAL study data readout, the previously conservatively priced Greater China rights are set to revert to a fair value assessment framework. 3D189 is poised for a dual valuation recovery driven by the "removal of a risk discount" and "clinical data realization." However, this is not the endpoint but the starting point for value release. When a previously uncertain investigational product gradually transforms into a quantifiable core asset with complete regional rights, a clear commercial pathway, and a solid sales model, the market's re-anchoring of its valuation is simply a matter of time.
Comments